Improving Solubility 2008 October 27-29, 2008 Philadelphia, PA
This year’s Improving Solubility conference is essential for scientists working with poorly soluble drugs. With the increased number of poorly soluble drugs coming to the market, expansion of pipelines, effective research investment, and the incorporation of the correct strategy, it is vital for scientists working with poorly soluble drugs to ensure that they have the best techniques, expertise, and technologies to produce and develop drugs that are more soluble.
This conference, now back in the U.S., will provide the necessary updates, cutting edge science, strategies, and technologies incorporated by other companies that will enable you to find out what best practice is for you.
What are the benefits of attending?
* Actively seek new and improved ways to understand the importance of solubility in exposure during preclinical and clinical phases, and what parameters to control
* Avoid overcomplicating preclinical and clinical exposure issues
* Identifying compounds that will have issues during preclinical and clinical phases, and what you can do
* Build a higher probability of a new drug passing through the development pipeline
* Build an effective research strategy for the unique properties of a molecule
* Improve efficiency and throughput in testing compounds and develop good strategies to deal with this in formulation
Who will I meet and who will be speaking?
Early confirmed speakers:
* Annette Bak, PhD, Associate Director, Preformulation & Basic Research Support, Merck & Co., Inc.
* Caroline McGregor, PhD, Research Fellow, Merck & Co., Inc.
* Mitchell Friedman, PhD, Director of Toxicology, Takeda Pharmaceuticals
* Susan Wendel, PhD, Associate Director, ChemPharm Leader, Johnson & Johnson Pharmaceutical R&D
* Michael Kennedy, PhD, Senior Scientist, Pharmaceuticals, Amgen, Inc.
* Shawn Yin, PhD, Sr. Research Investigator II, Group Leader of Form Chemistry and Characterization Group, A R & D, Research & Development, Bristol Myers Squibb
* Xiaoming Sean Chen, PhD, Principal Scientist, Schering-Plough Research Institute
* Yun Alelyunas, PhD, Principal Scientist, Head of Physical Team, AstraZeneca
* Li Di, PhD, Principal Research Scientist, Wyeth Research
* Chong-Hui Gu, PhD, Scientist, Vertex Pharmaceuticals
* Shirlynn Chen, PhD, Senior Principal Scientist, Boehringer Ingelheim
* Jianling Wang, PhD, Head, ADME Profiling Cambridge, MAP, Novartis Institutes for Biomedical Research
* Ritesh Sanghvi, PhD, Assistant Research Scientist, Forest Laboratories
* Alex Avdeef, PhD, CEO/CSO, PIon Inc
Who should attend:
Scientists, Chemists, Research Leaders/Fellows/Advisors, Directors, Heads, & Managers specializing in:
* Discovery R&D
* Preclinical Development
* Preformulation
* Formulation
* Medicinal Chemistry
* Analytical Chemistry
* Chemical Development
* Product Development
* Drug Delivery
* Drug Discovery
* Toxicology
* Pharmaceutics
* Physiochemistry
* Chemical Engineering
* Solid States
* Process R&D
* Bioavailability
